Global Peptide Therapeutics Market 2025-2035

Description

List of Tables

Peptide Therapeutics Market Size, Share & Trends Analysis Report by Route of Administration (Oral, and Parenteral), by Drug Type (Dulaglutide, Liraglutide, Semaglutide, Tirzepatide, Teriparatide, Goserelin, Leuprorelin, and Other), and by Application (Obesity, Diabetes, Cancer, Infectious Diseases (Hepatitis), Gastrointestinal Disorders, Central Nervous System Disorders, Respiratory Disorders, and Others (AIDS, Personal Care and Cosmetics, and Other)) Forecast Period (2025-2035)

Industry Overview

Peptide therapeutics market was valued at $45.5 million in 2024 and is projected to reach $121.6 million by 2035, growing at a CAGR of 9.4% during the forecast period (2025-2035). The peptide therapeutics market is primarily driven by the extensive use of peptide therapeutics in managing diabetes and other chronic diseases. A key factor behind the increasing adoption of these therapies is the rising prevalence of metabolic disorders, such as obesity and diabetes. Insulin, which is a peptide hormone, is essential for regulating glucose levels in the body; an insulin deficiency can lead to diabetes. As diabetes rates continue to rise, the demand for insulin has also increased significantly.

Market Dynamics

Rising Prevalence of Chronic Disease Propels the Demand for Peptide Therapeutics

The increasing prevalence of chronic diseases such as cancer, diabetes, gastrointestinal disorders, and central nervous system disorders is fueling the demand for peptide drugs. For instance, as per the International Diabetes Foundation (IDF), in 2024, approximately 589 million adults will be living with diabetes globally, which is further expected to reach 853 million by 2045. The increasing prevalence of diabetes is encouraging manufacturers to develop improved care options. Additionally, the growing population of individuals with diabetes suggests that the target market will continue to expand in the near future.

Rising Demand for Cost-Efficient and Effective Drugs

The increasing demand for cost-effective and efficient drugs, combined with rapid research and development (R&D) activities to create innovative treatments, is expected to drive market growth during the forecast period. For instance, in April 2025, Sai Life Sciences, a contract research, development, and manufacturing organization (CRDMO), launched a new dedicated peptide research center at its integrated R&D campus in Hyderabad, India.

Market Segmentation

Based on the route of administration, the market is segmented into oral and parenteral.
Based on the drug type, the market is segmented into dulaglutide, liraglutide, semaglutide, tirzepatide, teriparatide, goserelin, leuprorelin, and other.
Based on the application, the market is segmented into obesity, diabetes, cancer, infectious diseases (hepatitis), gastrointestinal disorders, central nervous system disorders, respiratory disorders, and others (aids, personal care, and cosmetics, and others).

Cancer Segment to Contribute a Major Share in the Peptide Therapeutics Market

Among the different market segments, the cancer segment, particularly tubes used for cancer treatment, holds a major share. Several factors contribute to the growth of this segment, including the increasing incidence of cancer globally. Cancer remains a leading cause of mortality in both developed and developing countries. For instance, in 2023, the Food and Drug Administration (FDA) approved several major drugs, such as tirzepatide (Mounjaro) for type 2 diabetes and leuprolide for prostate cancer.

Regional Outlook

The global peptide therapeutics market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

North America is Leading the Peptide Therapeutics Market

North America is anticipated to hold a significant share driven by the rising prevalence of diabetes, improved clinical outcomes, new formulations such as oral semaglutide, and a shift towards biologic treatments. Peptides are becoming increasingly favored over older small-molecule drugs. Regulatory agencies such as the US FDA and the International Council for Harmonisation (ICH) have established guidelines for analyzing synthesized biomolecules and biotechnological products. These guidelines specify criteria for the analysis of such therapeutics, further supporting innovation in the peptide therapeutics market.

Market Players Outlook

The major companies operating in the global peptide therapeutics market include AstraZeneca Plc, Eli Lilly and Company, GlaxoSmithKline plc, Novo Nordisk A/S, and Sanofi S.A. (Lantus). Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

In March 2025, Eli Lilly launched Mounjaro (tirzepatide) in India, a drug designed for the treatment of Type 2 diabetes and obesity, approved by the Central Drugs Standard Control Organization (CDSCO). Mounjaro pricing is ₹3,500 ($40.6) for a 2.5 mg vial and ₹4,375 ($50.7) for a 5 mg vial.
In January 2025, Novo Nordisk announced that the US FDA approved Ozempic. This medication helps reduce the risk of worsening kidney disease, kidney failure (end-stage kidney disease), and death from cardiovascular disease in adults with type 2 diabetes and chronic kidney disease (CKD).

The Report Covers:

Market value data analysis of 2024 and forecast to 2035.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global peptide therapeutics market. Based on the availability of data, information related to new products and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2028916

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Global Peptide Therapeutics Market Sales Analysis - Route of Administration | Drug Type | Application ($ Million)
Peptide Therapeutics Market Sales Performance of Top Countries
1.1. Research Methodology
Primary Research Approach
Secondary Research Approach
1.2. Market Snapshot

2. Market Overview and Insights

2.1. Scope of the Study
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Peptide Therapeutics Market Trends
- 2.2.2. Market Recommendations

3. Market Determinants

3.1. Market Drivers
- 3.1.1. Drivers For the Global Peptide Therapeutics Market: Impact Analysis
3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For the Global Peptide Therapeutics Market: Impact Analysis
3.3. Market Opportunities
- 3.3.1. Opportunities For the Global Peptide Therapeutics Market: Impact Analysis

4. Competitive Landscape

4.1. Competitive Dashboard - Peptide Therapeutics Market Revenue and Share by Manufacturers
Peptide Therapeutics Product Comparison Analysis
Top Market Player Ranking Matrix
4.2. Key Company Analysis
- 4.2.1. AstraZeneca Plc
  - 4.2.1.1. Overview
  - 4.2.1.2. Product Portfolio
  - 4.2.1.3. Financial Analysis (Subject to Data Availability)
  - 4.2.1.4. SWOT Analysis
  - 4.2.1.5. Business Strategy
- 4.2.2. Eli Lilly and Company
  - 4.2.2.1. Overview
  - 4.2.2.2. Product Portfolio
  - 4.2.2.3. Financial Analysis (Subject to Data Availability)
  - 4.2.2.4. SWOT Analysis
  - 4.2.2.5. Business Strategy
- 4.2.3. GlaxoSmithKline plc
  - 4.2.3.1. Overview
  - 4.2.3.2. Product Portfolio
  - 4.2.3.3. Financial Analysis (Subject to Data Availability)
  - 4.2.3.4. SWOT Analysis
  - 4.2.3.5. Business Strategy
- 4.2.4. Novo Nordisk A/S
  - 4.2.4.1. Overview
  - 4.2.4.2. Product Portfolio
  - 4.2.4.3. Financial Analysis (Subject to Data Availability)
  - 4.2.4.4. SWOT Analysis
  - 4.2.4.5. Business Strategy
- 4.2.5. Sanofi S.A. (Lantus)
  - 4.2.5.1. Overview
  - 4.2.5.2. Product Portfolio
  - 4.2.5.3. Financial Analysis (Subject to Data Availability)
  - 4.2.5.4. SWOT Analysis
  - 4.2.5.5. Business Strategy
4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Product Launch
- 4.3.3. Partnership And Collaboration

5. Global Peptide Therapeutics Market Sales Analysis by Route of Administration ($ Million)

5.1. Oral
5.2. Parenteral

6. Global Peptide Therapeutics Market Sales Analysis by Drug Type ($ Million)

6.1. Dulaglutide
6.2. Liraglutide
6.3. Semaglutide
6.4. Tirzepatide
6.5. Teriparatide
6.6. Goserelin
6.7. Leuprorelin
6.8. Other

7. Global Peptide Therapeutics Market Sales Analysis by Application ($ Million)

7.1. Obesity
7.2. Diabetes
7.3. Cancer
7.4. Infectious Diseases (Hepatitis)
7.5. Gastrointestinal Disorders
7.6. Central Nervous System Disorders
7.7. Respiratory Disorders
7.8. Others (AIDS, Personal Care and Cosmetics, and Other)

8. Regional Analysis

8.1. North American Peptide Therapeutics Market Sales Analysis - Route of Administration | Drug Type | Application | Country ($ Million)
Macroeconomic Factors for North America
- 8.1.1. United States
- 8.1.2. Canada
8.2. European Peptide Therapeutics Market Sales Analysis - Route of Administration | Drug Type | Application | Country ($ Million)
Macroeconomic Factors for Europe
- 8.2.1. UK
- 8.2.2. Germany
- 8.2.3. Italy
- 8.2.4. Spain
- 8.2.5. France
- 8.2.6. Russia
- 8.2.7. Rest of Europe
8.3. Asia-Pacific Peptide Therapeutics Market Sales Analysis - Route of Administration | Drug Type | Application | Country ($ Million)
Macroeconomic Factors for Asia-Pacific
- 8.3.1. China
- 8.3.2. Japan
- 8.3.3. South Korea
- 8.3.4. India
- 8.3.5. Australia & New Zealand
- 8.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- 8.3.7. Rest of Asia-Pacific
8.4. Rest of the World Peptide Therapeutics Market Sales Analysis - Route of Administration | Drug Type | Application | Country ($ Million)
Macroeconomic Factors for the Rest of the World
- 8.4.1. Latin America
- 8.4.2. Middle East and Africa

9. Company Profiles

9.1. Agilent Technologies, Inc.
- 9.1.1. Quick Facts
- 9.1.2. Company Overview
- 9.1.3. Product Portfolio
- 9.1.4. Business Strategies
9.2. AstraZeneca Plc
- 9.2.1. Quick Facts
- 9.2.2. Company Overview
- 9.2.3. Product Portfolio
- 9.2.4. Business Strategies
9.3. AmbioPharm Inc.
- 9.3.1. Quick Facts
- 9.3.2. Company Overview
- 9.3.3. Product Portfolio
- 9.3.4. Business Strategies
9.4. Bachem Group
- 9.4.1. Quick Facts
- 9.4.2. Company Overview
- 9.4.3. Product Portfolio
- 9.4.4. Business Strategies
9.5. Biosynth Ltd.
- 9.5.1. Quick Facts
- 9.5.2. Company Overview
- 9.5.3. Product Portfolio
- 9.5.4. Business Strategies
9.6. Corden Pharma International GmbH
- 9.6.1. Quick Facts
- 9.6.2. Company Overview
- 9.6.3. Product Portfolio
- 9.6.4. Business Strategies
9.7. CSBio
- 9.7.1. Quick Facts
- 9.7.2. Company Overview
- 9.7.3. Product Portfolio
- 9.7.4. Business Strategies
9.8. ChinaPeptides CO., Ltd.
- 9.8.1. Quick Facts
- 9.8.2. Company Overview
- 9.8.3. Product Portfolio
- 9.8.4. Business Strategies
9.9. Eli Lilly and Company
- 9.9.1. Quick Facts
- 9.9.2. Company Overview
- 9.9.3. Product Portfolio
- 9.9.4. Business Strategies
9.10. F. Hoffmann-La Roche Ltd.
- 9.10.1. Quick Facts
- 9.10.2. Company Overview
- 9.10.3. Product Portfolio
- 9.10.4. Business Strategies
9.11. GenScript Biotech Corp.
- 9.11.1. Quick Facts
- 9.11.2. Company Overview
- 9.11.3. Product Portfolio
- 9.11.4. Business Strategies
9.12. GlaxoSmithKline plc
- 9.12.1. Quick Facts
- 9.12.2. Company Overview
- 9.12.3. Product Portfolio
- 9.12.4. Business Strategies
9.13. Merck & Co. Inc.
- 9.13.1. Quick Facts
- 9.13.2. Company Overview
- 9.13.3. Product Portfolio
- 9.13.4. Business Strategies
9.14. Novo Nordisk A/S
- 9.14.1. Quick Facts
- 9.14.2. Company Overview
- 9.14.3. Product Portfolio
- 9.14.4. Business Strategies
9.15. PolyPeptide Group AG
- 9.15.1. Quick Facts
- 9.15.2. Company Overview
- 9.15.3. Product Portfolio
- 9.15.4. Business Strategies
9.16. Sanofi S.A. (Lantus)
- 9.16.1. Quick Facts
- 9.16.2. Company Overview
- 9.16.3. Product Portfolio
- 9.16.4. Business Strategies
9.17. ScinoPharm Taiwan, Ltd.
- 9.17.1. Quick Facts
- 9.17.2. Company Overview
- 9.17.3. Product Portfolio
- 9.17.4. Business Strategies
9.18. Thermo Fisher Scientific Inc.
- 9.18.1. Quick Facts
- 9.18.2. Company Overview
- 9.18.3. Product Portfolio
- 9.18.4. Business Strategies
9.19. Takeda Pharmaceutical Co. Ltd.
- 9.19.1. Quick Facts
- 9.19.2. Company Overview
- 9.19.3. Product Portfolio
- 9.19.4. Business Strategies
9.20. Teva Pharmaceutical Industries Ltd. (TAPI)
- 9.20.1. Quick Facts
- 9.20.2. Company Overview
- 9.20.3. Product Portfolio
- 9.20.4. Business Strategies